Trial Profile
A Randomized Multicenter Trial of Neoadjuvant Taxotere (T) and Adriamycin/Cytoxan (Ac): A Validation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2020
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms TACAC
- 16 Jul 2020 Status changed from active, no longer recruiting to completed.
- 31 Jan 2019 Planned End Date changed from 1 Sep 2017 to 1 Sep 2020.
- 26 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.